NanoEntek: 2026 Q1 Consolidated Revenue 10,491 Mln Won, Operating Profit 149 Mln Won
Consolidated revenue 10,491 mln won (up 31.7% YoY), operating profit 149 mln won, net income 1,447 mln won, basic EPS 38 won
Debt ratio 9.38% (very low), no borrowings, abundant liquidity with cash 12,304 mln won and short-term financial products 24,450 mln won
Completed comprehensive stock exchange in Oct 2025 to make AAI Healthcare a wholly owned subsidiary; healthcare service segment added 2,070 mln won in revenue
R&D expenses 994 mln won (9.48% of revenue); continued FDA/CE approvals for products (FREND, ADAM-rWBC, ADAMⅡ-CD34, etc.)
One pending lawsuit (claim amount 502 mln won) under appeal; related provision of 404 mln won recorded
Shareholder returns: no dividends; out of 249,537 treasury shares, 228,000 granted as restricted stock to employees (board approval Mar 16, 2026)